Article: Sunesis Prices $42M IPO To Fuel Oncology Pipeline.

Article: ENDO'S LARGEST SHAREHOLDER SELLING STOCK WORTH $232.5M.(Endo ...
BIOWORLD Today;  July 3, 2003 ;     700+ words ... ... through the sale of 15 million shares. Endo Pharma LLC, an affiliate of private equity ... imposed quiet period. After the sale, Endo Pharma LLC will hold about 64 percent of Endo ... the same price. Prior to the sale, Endo Pharma LLC controlled about 75 percent of Endo ...

Article: Jubilant enters into a collaboration with Endo ...
PTI - The Press Trust of India Ltd.;  June 11, 2009 ;     611 words ...Jubilant enters into a collaboration with Endo Pharma Mumbai, June 11 (PTI) Drug firm Jubilant Organosys today ... entered into a discovery and development collaboration with Endo Pharma, Jubilant Organosys said in a filing to the Bombay Stock ...

Article: Endo Pharma sees 2nd-qtr profits slump.(ENDO ...
Pharma Marketletter;  July 26, 2004 ;     700 words ...US pain management specialist firm Endo Pharmaceuticals saw second-quarter 2004 earnings slump on generic competition for Percocet (acetaminophen and oxycodone) but now pins hopes on Frova (frovatriptan), rights to which it has just acquired from the UK's Vernalis (see page 2), and its own

Article: Endo Pharma converting to own sales reps.
Pharma Marketletter;  September 22, 2003 ;     331 words ...Endo Pharmaceuticals says it has exercised its option to convert its community-based contract sales force to Endo employees from the contract sales organization Ventiv Health US Sales, effective December 15, 2003. This brings the firm's internal sales force to a total of 231 sales representatives.

Article: Endo Pharma issues 2005 guidance.(Brief Article)
Pharma Marketletter;  January 3, 2005 ;     689 words ...US pain management specialist Endo Pharmaceuticals says that it expects net sales in the year ending December 31, 2005, to be approximately $650-$660 million. The company estimates earnings per share for 2005 to be around $1.18-$1.20 and adjusted EPS to be some $1.19-$1.21, which excludes estimated

Article: Vernalis/Endo Pharma withdraw Frova sNDA.
Pharma Marketletter;  April 14, 2008 ;     429 words ...UK drugmaker Vernalis says that its US development partner Endo Pharmaceuticals has notified the Food and Drug Administration of the withdrawal of a supplemental New Drug Application without prejudice to refiling for migraine drug Frova (frovatriptan succinate) 2.5 mg tablets. The sNDA was for the

Article: Endo Announces Pricing of Secondary Offering of Common Stock.
PR Newswire;  July 1, 2003 ;     700+ words ... ... outstanding shares. Endo Pharma LLC is an affiliate of ... ownership interest in Endo Pharma LLC. In this proposed ... completion of the offering, Endo Pharma LLC will hold approximately ... 388 Greenwich Street, New York, New York 10013, and ...